Core Viewpoint - The company, 加科思-B, has entered into a licensing and collaboration agreement with AstraZeneca AB to develop and commercialize the pan-KRAS inhibitor JAB-23E73, which includes significant financial terms and joint development responsibilities in specific regions [1]. Group 1: Agreement Details - The agreement grants AstraZeneca an exclusive license to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1]. - In mainland China, the product will be jointly developed and commercially collaborated under a governance framework established in the agreement [1]. Group 2: Financial Terms - 北京加科思 is entitled to receive an upfront payment of $100 million from AstraZeneca [1]. - The company is also eligible for additional milestone payments that could total up to $1.915 billion upon achieving various development, regulatory, and commercial milestones [1]. - Upon successful commercialization of the licensed product, 北京加科思 will receive tiered royalties based on the net sales of the product [1].

Core Viewpoint - The agreement between Beijing JACOS and AstraZeneca for the development and commercialization of the pan-KRAS inhibitor JAB-23E73 represents a significant collaboration in the oncology sector, with potential financial benefits for Beijing JACOS through upfront and milestone payments [1] Group 1: Agreement Details - Beijing JACOS has entered into a licensing and collaboration agreement with AstraZeneca for the pan-KRAS inhibitor JAB-23E73 [1] - AstraZeneca is granted exclusive rights to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding mainland China [1] - In mainland China, the product will be co-developed and co-commercialized by both parties under a governance framework established in the agreement [1] Group 2: Financial Implications - Beijing JACOS is entitled to receive an upfront payment of $100 million from AstraZeneca [1] - The company may receive additional milestone payments totaling up to $1.915 billion upon achieving certain development, regulatory, and commercial milestones [1] - Upon successful commercialization of the product, Beijing JACOS will earn tiered royalties based on the net sales of the licensed product [1]

Core Viewpoint - The collaboration between Beijing JACOS and AstraZeneca involves the development and commercialization of the KRAS inhibitor JAB-23E73, with AstraZeneca receiving exclusive global rights outside of China [1] Group 1: Agreement Details - Beijing JACOS has entered into a licensing and collaboration agreement with AstraZeneca for the development of JAB-23E73 [1] - AstraZeneca will be responsible for all costs and activities related to the further development and commercialization of JAB-23E73 in its designated regions [1] - The agreement includes a joint development and commercialization framework for the product in China, excluding Hong Kong, Macau, and Taiwan [1] Group 2: Financial Terms - Beijing JACOS is entitled to receive an upfront payment of $100 million from AstraZeneca [1] - Additional milestone payments could total up to $1.915 billion based on the achievement of various development, regulatory, and commercial milestones [1] - Upon successful commercialization, Beijing JACOS will receive tiered royalties based on the net sales of the licensed product [1]

Core Viewpoint - The agreement between Beijing JACOS and AstraZeneca for the development and commercialization of the pan-KRAS inhibitor JAB-23E73 represents a significant collaboration in the pharmaceutical industry, with potential financial benefits for Beijing JACOS through upfront and milestone payments [1] Group 1: Agreement Details - Beijing JACOS has entered into a licensing and collaboration agreement with AstraZeneca for the pan-KRAS inhibitor JAB-23E73 [1] - AstraZeneca is granted exclusive rights to research, develop, register, manufacture, and commercialize JAB-23E73 globally, excluding mainland China [1] - The collaboration will involve joint development and commercialization in mainland China, with both parties adhering to a governance framework outlined in the agreement [1] Group 2: Financial Implications - Beijing JACOS is entitled to receive an upfront payment of $100 million from AstraZeneca [1] - Additional potential milestone payments could total up to $1.915 billion, contingent upon achieving specific development, regulatory, and commercial milestones [1] - Upon successful commercialization of the licensed product, Beijing JACOS will receive tiered royalties based on the net sales of the product [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 JACOBIO PHARMACEUTICALS GROUP CO., LTD. 加 科 思 藥 業 集 團 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：1167） 內幕消息 與阿斯利康就泛KRAS抑制劑JAB-23E73訂立許可及合作協議 本公告由加科思藥業集團有限公司（「本公司」或「加科思」，連同其附屬公司，統稱「本集 團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例 第571章證券及期貨條例第XIVA部發佈。 根據許可及合作協議並在其條款及條件的規限下，北京加科思有權從阿斯利康收取1億美 元的首付款，並有資格在達成若干開發、監管及商業里程碑後獲得額外潛在總對價最高 可達19.15億美元的里程碑付款。此外，在許可產品成功商業化後，北京加科思將有權獲 得基於許可產品淨銷售額計算的分層特許權使用費。 根據許可及 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, recommending a focus on innovative drugs and sectors with improving performance, such as medical devices and upstream segments [3][4]. Core Insights - The pharmaceutical sector experienced a decline of 1.0% this week, ranking 17th among 31 sub-industries. The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, placing it 10th among the primary industries [2][4][7]. - Key events include Fosun Pharma granting exclusive global rights for its oral GLP-1 drug to Pfizer, with potential total payments reaching $2.085 billion. Additionally, Eli Lilly's GLP-1/GIP/GCGR agonist Retatrutide showed promising Phase III clinical data, achieving a weight loss of 28.7% over 68 weeks [3][14][17]. - The report highlights significant mergers and acquisitions, such as Sobi's acquisition of Arthrosi for $950 million upfront and $550 million in milestone payments, and Zhaoli Pharmaceutical's planned acquisition of a multi-trace element injection asset group for approximately RMB 356 million [3][15][22]. Market Performance - The pharmaceutical index decreased by 1.0% this week, while the Shanghai Composite Index fell by 0.3%. The overall performance of the pharmaceutical sector was ranked 17th among 31 sub-industries [2][4][6]. - The report details the performance of various sub-sectors, with notable declines in medical circulation (-4.2%), offline pharmacies (-4.3%), and blood products (-4.1%), while medical R&D outsourcing saw an increase of 3.7% [7][11]. Recent Key Events - The report discusses recent business developments, including the approval of Shanghai Pharma's new drug, and the change of control at Tailong Pharmaceutical, which will now be under Jiang Pharmaceutical Holdings [20][22]. - It also notes the IPO application of Shiyao Innovation, which was accepted with a market value of RMB 47.9 billion, focusing on health-related sectors and innovative drugs [23]. Company Valuation - The report provides a valuation table for key companies in the pharmaceutical sector, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2025 to 2027. For instance, Mindray Medical is projected to have a PE of 23 in 2025, while Hengrui Medicine is expected to have a PE of 48 [29].

Core Viewpoint - 加科思-B (01167) has seen a significant increase in stock price, rising over 11% and reaching 8.69 HKD, with a trading volume of 73.82 million HKD, following the announcement of a capital increase and equity transfer agreement with Haisheng Capital [1] Group 1 - 加科思 has received a first payment of 125 million RMB from Haisheng Capital, which enhances the company's cash reserves and supports the development of its innovative oncology therapy pipeline [1] - The agreement involves Haisheng Capital acquiring 80% of the equity in Beijing Jakesi's subsidiary, Jakesi Ruikang, with a total payment structure including a milestone payment of 75 million RMB [1] - Following the completion of this transaction, 加科思's ownership in Jakesi Ruikang will decrease to 10%, aligning with the company's strategic focus on key pipeline products targeting different critical cellular pathways in oncology [1]

Core Viewpoint - 加科思-B (01167.HK) experienced a significant increase in stock price, rising over 11% at one point and closing with a gain of 10.28% at HKD 8.69, with a trading volume of HKD 73.8233 million [1] Summary by Category - Stock Performance - 加科思-B's stock price rose by 10.28%, reaching HKD 8.69 [1] - The stock saw an intraday increase of over 11% [1] - The total trading volume was HKD 73.8233 million [1]

Core Viewpoint - 加科思-B (01167) has seen a significant stock price increase of over 11%, currently trading at 8.69 HKD, with a transaction volume of 73.82 million HKD, following the announcement of a capital increase and equity transfer agreement with Haisheng Capital [1] Group 1: Financial Developments - The company has received an initial payment of 125 million RMB from Haisheng Capital, which enhances its cash reserves and supports the development of its innovative oncology therapy pipeline [1] - The agreement includes a milestone payment of 75 million RMB, with Haisheng Capital acquiring 80% of the equity in Beijing Gakos under the terms of the capital increase and equity transfer agreement [1] Group 2: Strategic Focus - Following the completion of the transaction, the company's stake in Gakos will decrease to 10%, aligning with its strategic focus on key pipeline products targeting different critical cellular pathways in oncology [1]

加科思-B(01167)再涨超11%，截至发稿，涨10.28%，报8.69港元，成交额7382.33万港元。 消息面上，加科思近日宣布就其订立的增资协议及股权转让协议，已收到海松资本支付的1.25亿元的首 付款。该首付款的到账，进一步充盈了本集团的现金储备，也将为本集团后续创新肿瘤疗法管线研发的 推进提供助力。 据悉，加科思10月份公布，与海松资本及一名产业合作方签署增资及股权转让协议。根据本次协议，海 松资本将以人民币1.25亿元首付款及7500万元里程碑付款收购北京加科思旗下加科瑞康80%的股权。完 成后，北京加科思于加科瑞康持股将降至10%。公告称，该交易符合集团聚焦不同关键细胞通路的肿瘤 方向关键管线产品的战略发展。 ...